154 related articles for article (PubMed ID: 6153637)
21. Pseudomonas aeruginosa antigens as potential vaccines.
Stanislavsky ES; Lam JS
FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
[TBL] [Abstract][Full Text] [Related]
22. Induction of antituberculous immunity by polysaccharidic contaminants of crude ribosomal vaccines isolated from Mycobacterium bovis, strain BCG.
Portelance V; Boulanger RP; Brasseur R
Rev Can Biol; 1977 Sep; 36(3):265-75. PubMed ID: 928854
[TBL] [Abstract][Full Text] [Related]
23. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
24. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.
Lieberman MM; McKissock DC; Wright GL
Infect Immun; 1979 Feb; 23(2):509-21. PubMed ID: 106013
[TBL] [Abstract][Full Text] [Related]
25. Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV.
MacIntyre S; Lucken R; Owen P
Infect Immun; 1986 Apr; 52(1):76-84. PubMed ID: 3082762
[TBL] [Abstract][Full Text] [Related]
26. Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.
Lieberman MM; Wright GL; Wolcott KM; McKissock-Desoto DC
Infect Immun; 1980 Aug; 29(2):489-93. PubMed ID: 6783532
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine.
Barclay GR; Yap PL; McClelland DB; Jones RJ; Roe EA; McCann MC; Micklem LR; James K
J Med Microbiol; 1986 Feb; 21(1):87-90. PubMed ID: 3081727
[TBL] [Abstract][Full Text] [Related]
28. Analysis of immunity to infection with Salmonella typhimurium in outbred mice. II. Isolation and immunogenicity of the protective non-O antigenic component from ribosomal vaccine.
Kita E; Emoto M; Katsui N; Nishi K; Yasui K; Yasui K; Kashiba S
Immunology; 1987 Oct; 62(2):235-40. PubMed ID: 2445665
[TBL] [Abstract][Full Text] [Related]
29. Active and passive immunization with Pseudomonas aeruginosa ribosomal vaccines and antisera in the burned rat model.
Lieberman MM; Walker HL; Ayala E; Chapa I
J Surg Res; 1986 Feb; 40(2):138-44. PubMed ID: 3080639
[TBL] [Abstract][Full Text] [Related]
30. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
31. Immunologic basis for mouse protection provided by high-molecular-weight polysaccharide from immunotype 1 Pseudomonas aeruginosa.
Markham RB; Pier GB
Rev Infect Dis; 1983; 5 Suppl 5():S957-62. PubMed ID: 6419317
[TBL] [Abstract][Full Text] [Related]
32. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
[TBL] [Abstract][Full Text] [Related]
33. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli.
Finke M; Duchêne M; Eckhardt A; Domdey H; von Specht BU
Infect Immun; 1990 Jul; 58(7):2241-4. PubMed ID: 2114360
[TBL] [Abstract][Full Text] [Related]
34. Vaccines against Pseudomonas aeruginosa infection: 1. Experimental studies.
Stanislavsky ES; Joo I; Mashilova GM; Boolk VF; Boltutsy LG; Zakgeim DA; Severtśova MK; Yedvabnaya LS; Gladus MA; Fatkhinurova TI
Vaccine; 1985 Jun; 3(2):128-36. PubMed ID: 3929491
[TBL] [Abstract][Full Text] [Related]
35. Ribosomal vaccines. II. Specificity of the immune response to ribosomal ribonucleic acid and protein isolated from Salmonella typhimurium.
Johnson W
Infect Immun; 1973 Sep; 8(3):395-400. PubMed ID: 4199718
[TBL] [Abstract][Full Text] [Related]
36. Ribosomal vaccines: introduction to the study of ribosomal vaccines.
Dussourd d'Hinterland L
Arzneimittelforschung; 1980; 30(1a):122-5. PubMed ID: 6154466
[No Abstract] [Full Text] [Related]
37. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Lang AB; Schaad UB; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Cryz SJ
J Pediatr; 1995 Nov; 127(5):711-7. PubMed ID: 7472821
[TBL] [Abstract][Full Text] [Related]
38. [Cell-free Pseudomonas vaccine. IV. Laboratory trials of the effectiveness of experimental Pseudomonas vaccines].
Stanislavskiĭ ES; Joó I; Bulk VF; Zhvanetskaia MI; Mashilova GM
Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):25-9. PubMed ID: 6817559
[TBL] [Abstract][Full Text] [Related]
39. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.
Pier GB; Koles NL; Meluleni G; Hatano K; Pollack M
Infect Immun; 1994 Apr; 62(4):1137-43. PubMed ID: 8132318
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
